Branded Drug Companies are Successfully Asserting the Doctrine of Equivalents in Hatch-Waxman Litigation
Year of publication: |
[2022]
|
---|---|
Authors: | Holman, Christopher M. |
Publisher: |
[S.l.] : SSRN |
Subject: | Markenführung | Brand management | Arzneimittel | Pharmaceuticals |
Extent: | 1 Online-Ressource (34 p) |
---|---|
Series: | |
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments 2021 erstellt |
Other identifiers: | 10.2139/ssrn.4027544 [DOI] |
Source: | ECONIS - Online Catalogue of the ZBW |
-
Umbrella branding in pharmaceutical markets
Suppliet, Moritz, (2017)
-
A model of the role of free drug samples in physicians' prescription decisions
Joseph, Kissan, (2009)
-
Kvesik, Dennis Z., (2009)
- More ...
-
Congress Considering Legislation Aimed at Increasing Competition in Pharmaceuticals
Holman, Christopher M., (2020)
-
Antibody Claims and the Evolution of the Written Description / Enablement Requirement
Tu, S. Sean, (2022)
-
Biotechnology's Prescription for Patent Reform
Holman, Christopher M., (2014)
- More ...